As GSK, Merck Slash Rotavirus Vaccine Prices, Bharat Biotech Eyes Supplies At $1 Per Shot
This article was originally published in The Pink Sheet Daily
Executive Summary
Bharat Biotech's rotavirus development is a public-private initiative with partners including the Indian government, CDC and NIH.
You may also be interested in...
Merck Aims For Deep Dive Into India's Vaccines Market With RotaTeq Launch; May Bring In Many More
MUMBAI - New Jersey-headquartered Merck & Co's Indian affiliate MSD India is fanning out 150 trained medical representatives in 17 cities to promote a basket of three vaccines - a moderately aggressive measure as compared to a few other similar-sized companies having presence in the segment
Pfizer And GSK Use Novel Funding Mechanism To Send Blockbuster Vaccines To World's Poorest Countries
Pfizer and GlaxoSmithKline have agreed, after four years of negotiations, to supply their leading pneumococcal vaccines at significantly reduced prices to the world's poorest countries, signaling the first use of a novel funding mechanism that could create similar deals to bring new drugs to developing countries
As Pfizer-Wyeth Combine Eye Vaccines Business, Novartis, GSK, Sanofi-Aventis And Indian Companies Brace For The Challenge
MUMBAI - These may be early days for Pfizer and Wyeth to analyze growth strategies of their vaccines business in emerging markets like India, but existing players like GlaxoSmithKline, Merck, Novartis and a host of home-grown companies like Panacea Biotec, Serum Institute and Shantha Biotech already seem well positioned to accelerate their growth in the quickly emerging vaccines market
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: